Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:KDMN
CUSIPN/A
Phone212-308-6000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.03
Quick Ratio1.02
Price-To-Earnings
Trailing P/E Ratio-2.73
Forward P/E Ratio-4.03
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.26 million
Price / Sales24.87
Cash FlowN/A
Price / CashN/A
Book Value($0.49) per share
Price / Book-7.90
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-79,770,000.00
Net Margins-1,159.00%
Return on EquityN/A
Return on Assets-115.90%
Miscellaneous
Employees101
Outstanding Shares78,790,000
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Holdings Inc (NYSE:KDMN) announced its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.03. The company earned $0.43 million during the quarter, compared to analysts' expectations of $2.67 million. View Kadmon's Earnings History.
What price target have analysts set for KDMN?
4 brokers have issued 12 month target prices for Kadmon's shares. Their forecasts range from $3.00 to $25.00. On average, they anticipate Kadmon's stock price to reach $13.25 in the next year. View Analyst Ratings for Kadmon.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Arrowhead Pharmaceuticals (ARWR), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Wave Life Sciences (WVE), Reata Pharmaceuticals (RETA), Esperion Therapeutics (ESPR), Flexion Therapeutics (FLXN), Intra-Cellular Therapies (ITCI), Dynavax Technologies (DVAX), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT) and CytomX Therapeutics (CTMX).
Who are Kadmon's key executives?
Kadmon's management team includes the folowing people:
- Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)
- Mr. Konstantin Poukalov, Exec. VP, CFO & Principal Accounting Officer (Age 34)
- Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)
- Dr. John L. Ryan, Chief Medical Officer & Exec. VP (Age 75)
- Wei Chen Ph.D., Associate Director of Immunology
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Has Kadmon been receiving favorable news coverage?
Media stories about KDMN stock have been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kadmon earned a media sentiment score of 0.22 on Accern's scale. They also gave media headlines about the company an impact score of 47.45 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Kadmon's major shareholders?
Kadmon's stock is owned by many different of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (7.55%), Millennium Management LLC (2.34%), BlackRock Inc. (1.96%), Sphera Funds Management LTD. (1.89%), Spark Investment Management LLC (0.47%) and Asymmetry Capital Management L.P. (0.25%). Company insiders that own Kadmon stock include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon.
Which major investors are buying Kadmon stock?
KDMN stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Acuta Capital Partners LLC, Sphera Funds Management LTD., Asymmetry Capital Management L.P., Sofinnova Ventures Inc, Tibra Equities Europe Ltd and Spark Investment Management LLC. Company insiders that have bought Kadmon stock in the last two years include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon.
How do I buy shares of Kadmon?
Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of KDMN stock can currently be purchased for approximately $3.87.
How big of a company is Kadmon?
Kadmon has a market capitalization of $293.12 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.
How can I contact Kadmon?
Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (KDMN)
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
